Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

Radiopharm Theranostics / Equity Bottom-Up

<ul><li>Radiopharm Theranostics is advancing a portfolio of imaging and therapeutic radiopharmaceutical candidates in oncology.</li><li>Its approach recognizes the opportunities in tumors beyond prostate, thyroid & neuroendocrine targets originated by precision oncology & validated by clinical trials & regulatory approval.</li><li>RAD101, an 18F radioisotope developed to image brain metastases is the most advanced asset.</li></ul>

Radiopharm Theranostics is advancing a portfolio of imaging and therapeutic radiopharmaceutical candidates in oncology.Its approach recognizes the opportunities in tumors beyond prostate, thyroid & neuroendocrine targets originated by precision oncology & validated by clinical trials & regulatory approval.RAD101, an 18F radioisotope developed to image brain metastases is the most advanced asset.

RADX: RAD101: Imaging Recurring Brain Metastases

<ul>
<li>Radiopharm Theranostics is advancing a portfolio of imaging and therapeutic radiopharmaceutical candidates in oncology.</li>
<li>Its approach recognizes the opportunities in tumors beyond prostate, thyroid &amp; neuroendocrine targets originated by precision oncology &amp; validated by clinical trials &amp; regulatory approval.</li>
<li>RAD101, an 18F radioisotope imaging brain metastases is the most advanced asset.</li>
</ul>


Radiopharm Theranostics is advancing a portfolio of imaging and therapeutic radiopharmaceutical candidates in oncology.
Its approach recognizes the opportunities in tumors beyond prostate, thyroid &amp; neuroendocrine targets originated by precision oncology &amp; validated by clinical trials &amp; regulatory approval.
RAD101, an 18F radioisotope imaging brain metastases is the most advanced asset.


RADX: Initiating Coverage - Adding a Radioisotope to Precision Oncology

United States

Radiopharm Theranostics Limited operates as a biotech company. The Company focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. Radiopharm Theranostics serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Radiopharm Theranostics (RADX US)

RADX: Program and Financial Updates

Radiopharm Theranostics is advancing a portfolio of imaging and therapeutic radiopharmaceutical candidates in oncology. Its approach recognizes...

Zacks Small Cap Research

RADX: RAD101: Imaging Recurring Brain Metastases

Radiopharm Theranostics is advancing a portfolio of imaging and therapeutic radiopharmaceutical candidates in oncology. Its approach recognizes...

Zacks Small Cap Research

RADX: Prostate Cancer KOL Summary

Radiopharm Theranostics is advancing a portfolio of imaging and therapeutic radiopharmaceutical candidates in oncology. Its approach recognizes...

Zacks Small Cap Research

RADX: July 2025 Update

Radiopharm Theranostics is advancing a portfolio of imaging and therapeutic radiopharmaceutical candidates in oncology. Its approach recognizes...

Zacks Small Cap Research

RADX: Initiating Coverage - Adding a Radioisotope to Precision Oncology

Radiopharm Theranostics is advancing a portfolio of imaging and therapeutic radiopharmaceutical candidates in oncology. ts approach recognizes the...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)